ArticleJournal of clinical medicine2025

Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn's Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study.

Alessandro Massano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.